# An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

> **NCT02187055** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 1152 (actual)

## Conditions studied

- Rhematoid Arthritis

## Interventions

- **DRUG:** Tofacitinib with methotrexate
- **DRUG:** Tofacitinib without methotrexate
- **BIOLOGICAL:** Adalimumab with methotrexate

## Key facts

- **NCT ID:** NCT02187055
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 1152 (ACTUAL)
- **Last updated:** 2018-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02187055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02187055, "An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02187055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*